Boston Scientific Files 8-K for Senior Notes
Ticker: BSX · Form: 8-K · Filed: 2024-11-15T00:00:00.000Z
Sentiment: neutral
Topics: debt-issuance, financing
Related Tickers: BSX
TL;DR
BSX is issuing new debt, filing 8-K for notes due 2027.
AI Summary
Boston Scientific Corporation (BSX) announced on November 15, 2024, that it has entered into an agreement for senior notes due in 2027. The filing does not disclose specific financial details or the exact purpose of these notes, but it is a standard disclosure for debt issuance.
Why It Matters
This filing indicates Boston Scientific is raising capital through debt, which could be for general corporate purposes, acquisitions, or refinancing existing debt.
Risk Assessment
Risk Level: low — This is a routine debt issuance filing with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- Boston Scientific Corporation (company) — Registrant
- BSX (company) — Ticker Symbol
- November 15, 2024 (date) — Report Date
- 2027 (date) — Maturity Year of Senior Notes
FAQ
What is the principal amount of the senior notes due 2027?
The filing does not specify the principal amount of the senior notes due 2027.
What is the interest rate on the senior notes due 2027?
The filing does not disclose the interest rate for the senior notes due 2027.
What is the intended use of the proceeds from the senior notes due 2027?
The filing does not detail the specific use of proceeds for the senior notes due 2027.
When was the agreement for the senior notes due 2027 finalized?
The filing indicates the report date is November 15, 2024, suggesting the agreement was likely finalized around this date.
Are there any specific covenants or conditions associated with these senior notes?
The filing does not provide details on specific covenants or conditions for the senior notes due 2027.
From the Filing
0000885725-24-000078.txt : 20241115 0000885725-24-000078.hdr.sgml : 20241115 20241115160224 ACCESSION NUMBER: 0000885725-24-000078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241115 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241115 DATE AS OF CHANGE: 20241115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 241467724 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20241115.htm 8-K bsx-20241115 0000885725 false 0000885725 2024-11-15 2024-11-15 0000885725 us-gaap:CommonStockMember 2024-11-15 2024-11-15 0000885725 bsx:SeniorNotedue2027Member 2024-11-15 2024-11-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): November 15, 2024 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 8.01 Other Events. On November 15, 2024, Boston Scientific Corporation (the “Company”) completed its acquisition of Axonics, Inc. (“Axonics”), a public medical technology company focused on the development and commercialization of differentiated devices to treat urina